688656 Hob Biotech Group Corp., Ltd
- 24.96
- -0.34-1.34%
Hob Biotech Group Corp., Ltd News
Haoubo (688656.SH): Net profit of 3.8096 million yuan in the first quarter decreased by 31.50% year-on-year
On April 28, Ge Longhui (688656.SH) released its report for the first quarter of 2024. During the reporting period, it achieved operating income of 85.5998 million yuan, an increase of 5.97%; net profit attributable to shareholders of listed companies was 38.096 million yuan, a year-on-year decrease of 31.50%; net profit attributable to shareholders of listed companies after deducting non-recurring gains and losses was 2.5841 million yuan, a year-on-year decrease of 29.62%; and basic earnings per share were 0.06 yuan.
Haoubo (688656): Revenue increased 23%, deployed desensitizing drugs to create a fully closed-loop service for precise treatment
Company: The company released its 2023 annual report. In 2023, it achieved operating income of 394 million yuan (yoy +23.10%), net profit attributable to mother of 47 million yuan (yoy +13.64%), net profit not attributable to mother
Haoubo (688656.SH): Net profit increased by 13.64% to 473.34 million yuan in 2023, plans to pay 10 to 4 yuan
On April 25, Ge Longhui (688656.SH) released its 2023 annual report, achieving operating income of 394 million yuan, up 23.10% year on year; net profit attributable to shareholders of listed companies was 473.314 million yuan, up 13.64% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 43.3049 million yuan, up 17.46% year on year; basic earnings per share were 0.75 yuan. It is proposed to pay a cash dividend of 4.0 yuan (tax included) for every 10 shares to all shareholders.
Haoubo (688656.SH): A total of 79,000 shares have been repurchased
Gelonghui, April 2, 丨 Haoubo (688656.SH) announced that as of March 31, 2024, the company had repurchased 78,968 shares through centralized bidding through the Shanghai Stock Exchange system, accounting for 0.125% of the company's total share capital of 63,058,328 shares. The highest price of the repurchase transaction was 25.79 yuan/share, the lowest price was 24.95 yuan/share, and the payment amount was 1,998,466.40 yuan (excluding transaction fees such as stamp duty and transaction fees).
Haoubo (688656.SH): 40,500 shares repurchased for the first time
Gelonghui (688656.SH) announced on March 26, 2024, that on March 26, 2024, the company repurchased 40,506 shares of the company's shares for the first time through centralized bidding transactions, accounting for 0.0642% of the company's total share capital of 63,058,328 shares. The highest price of the repurchase transaction was 25.79 yuan/share, the lowest price was 24.96 yuan/share, and the total amount of capital paid was RMB 1,025,182.19 (excluding transaction fees such as stamp duty and transaction fees).
Express News | Hao Oubo: Plans to buy back shares for 20 million yuan to 30 million yuan
Express News | More than 20 listed companies announced plans to repurchase or increase their holdings today, and Shanxi Fenjiu plans to increase their holdings by up to 200 million yuan
Haoubo (688656.SH): Net profit increased 15.06% year-on-year in 2023
Gelonghui, Feb. 2: Hao Oubo (688656.SH) announced the 2023 annual performance report. During the reporting period, the company achieved operating income of 394.5527 million yuan, an increase of 23.15% over the same period of the previous year; achieved operating profit of 56.0145 million yuan, an increase of 17.76% over the same period of the previous year; realized net profit attributable to owners of the parent company of 47.922 million yuan, an increase of 15.06% over the same period of the previous year; achieved net profit attributable to owners of the parent company after deducting non-recurring profit and loss 19.06%
HOB Biotech Group Corp.,Ltd (SHSE:688656) Shares May Have Slumped 28% But Getting In Cheap Is Still Unlikely
To the annoyance of some shareholders, HOB Biotech Group Corp.,Ltd (SHSE:688656) shares are down a considerable 28% in the last month, which continues a horrid run for the company. Instead of being
45 million restricted shares of Haoobo (688656.SH) will be listed and circulated from January 15
Hao Oubo (688656.SH) issued an announcement. The restricted shares listed and circulated this time are the company's initial public offering of restricted shares...
Haoubo (688656.SH): The subsidiary obtained 3 medical device registration certificates
On December 28, Gelonghui (688656.SH) announced that Hunan Haooubo Biomedical Co., Ltd., a wholly-owned subsidiary of the company, recently obtained 3 medical device registration certificates approved and issued by the Hunan Drug Administration. Product name: Anti-malagin antibody calibration product. This kit is used in conjunction with the anti-malagin antibody test kit (magnetic particle chemiluminescence method) produced by the company to calibrate the anti-malagin antibody detection system. Product name: Anti-malagin antibody quality control product. This kit is used in conjunction with the anti-malagin antibody test kit (magnetic particle chemiluminescence method) produced by the company.
Haoobo (688656): Performance meets expectations, B2C business accelerates layout
Key investment events: the company achieved operating income of 300 million yuan in the first three quarters of 2023 (+17.9%, year-on-year ratio in parentheses, same below); net profit of 38.63 million yuan (-13.1%); net profit of 38.63 million yuan (-13.1%); deduction of non-return net profit 34
Haoobo (688656.SH) released the first three quarter results, net profit of 386.339 million yuan, a year-on-year decrease of 13.13%
Hao Oubo (688656.SH) released the report for the third quarter of 2023. The company achieved operating income of 300 million in the first three quarters...
Haoobo (688656) 2023 Third Quarter Report Review: Performance growth is in line with expectations, desensitization treatment is worth looking forward to
Event: The company released its report for the third quarter of 2023. The first three quarters of 2023 achieved operating income of 300 million yuan, an increase of 17.89% over the previous year; net profit of 38.63 million yuan, a year-on-year decrease of 13.13%; non-return
Hao Oubo (688656.SH): Granting 1.62 million restricted shares to incentive recipients
Glonghui, October 9, 丨 Hao Oubo (688656.SH) announced that the company has decided that October 9, 2023 will be the grant date, and will grant 1.62 million restricted shares to 59 incentive recipients at a grant price of 15.93 yuan/share.
Hao Oubo (688656.SH) plans to introduce a restricted stock incentive plan of 1,817,000 shares with an award price of 15.93 yuan/share
Hao Oubo (688656.SH) disclosed the 2023 restricted stock incentive plan (draft). The incentive plan is planned...
Hao Oubo (688656.SH): Plans to launch sales and registration business of the Otok series of desensitizing drugs
GLONGHUI September 5 | Hao Oubo (688656.SH) announced that based on the strategic plan, combined with market development prospects and business layout, the sales and registration business of the Eurotec series of desensitizing drugs will be carried out with its own funds. The initial investment amount is about 35 million yuan. It is mainly used for sales, product procurement, inventory establishment, training and promotion of the Otok series products in the Lecheng Pioneer District Hospital. The registration process for Otok products in China will be carried out later. The capital for this investment comes from own funds. This transaction does not constitute a related transaction, nor does it constitute a major asset restructuring. The second phase of the project will rely on Otok to advance in Lecheng
Hao Oubo (688656.SH): Net profit for the first half of the year was 21.5713 million yuan, down 11.45% year on year
Glonghui, August 24, 丨 Hao Oubo (688656.SH) announced the 2023 semi-annual report. The reporting period achieved operating income of 191 million yuan, an increase of 25.95%; net profit attributable to shareholders of listed companies was 21.5713 million yuan, a year-on-year decrease of 11.45%; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 17.8957 million yuan, a year-on-year decrease of 15.53%; basic earnings per share were 0.34 yuan. During the reporting period, with the gradual recovery of the market, the company's revenue increased by 25.95% over the same period last year, and the company always attached importance to new product research and development
Haobo (688656.SH): Will expand to more countries and regions in the future
Glonway June 29丨Some investors asked Haobo (688656.SH): After the epidemic, I observed two phenomena. The symptoms of allergies that used to have symptoms became serious, and those that had no allergy symptoms before also began to develop. What does the company think of this trend? The price of a set of more than 200 quantitative allergen tests in Hong Kong is close to 10,000. Currently, the domestic allergen testing market is still very small, so the focus is on developing developed regions. How is the company expanding overseas markets? What measures have they all taken? Haoobo replied: Hello, Haoobo is one of the few in the world that has achieved self-exemption for chemiluminescence of nanomagnetic particles
Haobo (688656.SH): The company has always attached importance to equity incentives
GLONGHUI June 29丨Some investors asked Haoobo (688656.SH): Judging from the actual results completed in 2022, what specific measures does the company have in 2023 to ensure that it meets the assessment target B or A for equity incentives? Haoobo replied: Dear investors, hello! The company has always attached importance to equity incentives. In the future, the company will continue to enhance intrinsic value and make continuous efforts to improve business performance. At the same time, it also focuses on various forms of communication with the market and actively carries out various tasks. Under the premise of legal compliance with information disclosure, the company will continue to strengthen communication with investors to achieve the transmission of corporate value and maintain capital
Analysis
Price Target
No Data
